Tag Archives: U.S.

Shorter waits for new patients at VA than in private sector, U.S. study finds

(Reuters Health) – In many cases, veterans get a first appointment at VA hospitals quicker than the general public gets first appointments with health care providers, government researchers report. The researchers, all from the VA, compared wait times there for new patients to those for new patients in the private sector as determined by an… Read More »

Sen. Sanders, Rep. Cummings to introduce bill to lower U.S. drug prices

WASHINGTON (Reuters) – U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers. FILE PHOTO: A pharmacy employee looks for medication as she works to fill a prescription while working at a pharmacy in New York December 23, 2009. REUTERS/Lucas… Read More »

Medicare, Medicaid underpaid U.S. hospitals by $76.8 billion in 2017, American Hospital Association says

According to new data released by the American Hospital Association, Medicare and Medicaid underpaid U.S. hospitals by $ 76.8 billion in 2017. Medicare underpayments totaled $ 53.9 billion and Medicaid underpayments $ 22.9 billion for 2017. Meanwhile, in 2017, hospitals provided $ 38.4 billion in uncompensated care, the AHA said. THE IMPACT This means hospitals… Read More »

CanGaroo Envelope Now Cleared in U.S. to Protect Implantable Neurostimulators

Aziyo Biologics, out of Silver Springs, Maryland, won FDA clearance for its CanGaroo Envelope to be used with implantable neurostimulators. It has previously been cleared only for encapsulating implantable cardiac devices such as pacemakers and defibrillators. The CanGaroo Envelope is, contrary to what its name may imply, is a porcine extracellular matrix, essentially pig’s tissue with… Read More »

AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023

AbbVie is on a hot streak striking patent deals to protect its top drug, Humira. Even as Boehringer Ingelheim has opted to fight the company’s patent claims in court, Pfizer has decided it’s in its own best interest to settle on a late 2023 biosimilar launch date. Under a licensing agreement with AbbVie, Pfizer can… Read More »

AstraZeneca chief says Europe should pay more for drugs—and the U.S. should pay less

President Donald Trump has routinely bashed “global freeloading” on pharmaceuticals, and his administration last month unveiled a plan to try and lower some U.S. drug prices to international levels. Now, a top pharma CEO says he’s right—at least in principle. In an interview with Bloomberg TV, AstraZeneca CEO Pascal Soriot said a “readjustment” of prices,… Read More »